• Waldenström Macroglobulinemia
  • Melanoma
  • Bladder Cancer
  • Brain Cancer
  • Breast Cancer
  • Childhood Cancers
  • Gastric Cancer
  • Gynecologic Cancer
  • Head & Neck Cancer
  • Immunotherapy
  • Kidney Cancer
  • Leukemia
  • Liver Cancer
  • Lung Cancer
  • Lymphoma Cancer
  • Mesothelioma
  • MPN
  • MDS
  • Myeloma
  • Prostate Cancer
  • Rare Cancers
  • Sarcoma
  • Skin Cancer
  • Testicular Cancer
  • Thyroid Cancer

Bladder Cancer Advocacy Network Announces 2019 Bladder Cancer Research Innovation Awardee

Article

The Bladder Cancer Advocacy Network announced the recipient of its prestigious Bladder Cancer Research Innovation Award.

Today, the Bladder Cancer Advocacy Network (BCAN) announced the recipient of its prestigious Bladder Cancer Research Innovation Award. This year’s awardee is Philip Beachy, Ph.D., Professor of Urology at Stanford University. His research project will address the need for better treatments for recurrent bladder cancer CIS (carcinoma in-situ) and intermediate and high-risk non-muscle invasive bladder cancer (NMIBC).

BCAN’s Bladder Cancer Research Innovation Award, funded at $300,000 for two years, supports exceptionally novel and creative projects with great potential to produce breakthroughs in the management of bladder cancer.

“It is gratifying to provide funding for innovative bladder cancer research projects such as Dr. Beachy’s. This award supports research that is high-risk and has the potential for high-reward in new discoveries,” said Andrea Maddox Smith, CEO of the Bladder Cancer Advocacy Network. “These critical projects are not likely to be funded elsewhere. We are proud to continue to encourage innovation in the bladder cancer research community.”

Dr. Beachy’s project is titled “Transdifferentiation of fibroblasts to urothelial progenitors for definitive urothelial replacement therapy in non-muscle invasive bladder cancer.” Dr. Beachy’s approach involves replacing the diseased urothelium with healthy bladder urothelial progenitor cells. In addition to generating these bladder urothelial progenitors, he will also focus on developing methods for transplanting these cells into bladders afflicted with NMIBC using a carcinogen-based bladder cancer mouse model. Dr. Beachy intends to develop a diagnostic tool based on single-cell RNA sequencing of human patient samples to identify candidates for this potential therapy.

Dr. Beachy is an Ernest and Amelia Gallo Professor at Stanford University School of Medicine in Palo Alto, California and an Associate at Stanford's Institute of Stem Cell Biology and Regenerative Medicine.

The Bladder Cancer Advocacy Network’s (BCAN’s) mission is to increase public awareness about bladder cancer, advance bladder cancer research and, provide educational and support services for the bladder cancer community.

Related Videos
Woman with dark brown hair and pink lipstick wearing a light pink blouse with a light brown blazer. Patients should have conversations with their providers about treatments after receiving diagnoses.
Dr. Psutka in an interview with CURE
Dr. Sarah Psutka in an interview with CURE at the ASCO Annual Meeting
Kristie L. Kahl and Dr. Tracy L. Rose
Dr. Tracy Rose
Dr. Tracy L. Rose
Kristie L. Kahl and Tracy L. Rose
Kristie L. Kahl
Related Content